Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 33

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 33
---
 approval for its drug candidates within the timeline TELI anticipates, TELI will not be able to execute TELI’s business strategy effectively and TELI’s ability to substantially grow TELI’s revenues will be limited, which would have a material adverse impact on TELI’s long-term business, results of operations, financial condition, and prospects.

| 17 |

We are dependent on TELI’s current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.

Our ability to progress TELI’s plan will depend on TELI’s ability to clinically develop, gain regulatory approval for and ultimately commercialize TELI’s product candidates. TELI’s ability to successfully commercialize TELI’s product candidates will depend on, among other things, TELI’s ability to:

| ● | successfully                                                                                                                               
 complete pre-clinical and other nonclinical studies and clinical trials in a manner that allows us to progress TELI’s studies;             |
| ● | receive                                                                                                                                    
 IND acceptance and regulatory approvals from the FDA;                                                                                      |
| ● | produce,                                                                                                                                   
 through a validated process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently 
 large quantities of product candidates to permit successful commercialization;                                                             |
| ● | obtain                                                                                                                                     
 reimbursement from payers such as government health care programs and insurance companies and achieve commercially attractive levels       
 of pricing;                                                                                                                                |
| ● | secure                                                                                                                                     
 acceptance of TELI’s product candidates from physicians, health care payers, patients, and the medical community;                          |
| ● | create                                                                                                                                     
 positive publicity surrounding TELI’s product candidates;                                                                                  |
| ● | manage                                                                                                                                     
 TELI’s spending as costs and expenses increase due to clinical trials and commercialization; and                                           |
| ● | obtain                                                                                                                                     
 and enforce sufficient intellectual property rights for TELI’s product candidates.                                                         |

TELI’s failure or delay with respect to any of the factors above could have a material adverse effect on TELI’s business, results of operations and financial condition.

Results of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.

Any positive results from future pre-clinical testing of TELI’s product candidates and potential future clinical trials may not be predictive of the results from Phase I, Phase II or Phase III clinical trials. In addition, TELI’s interpretation of results derived from clinical data or TELI’s conclusions